2024
Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Luu B, Mehta-Shah N, Shree T, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Stevens P, Mishra A, Stuver R, Hampel P, Brammer J. Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort. Blood 2024, 144: 982-982. DOI: 10.1182/blood-2024-194242.Peer-Reviewed Original ResearchT-cell prolymphocytic leukemiaProgression-free survivalOverall survivalMedian OSFrontline treatmentT-PLL patientsTherapeutic outcomesMedian follow-up timeT-cell prolymphocytic leukemia cellsResponse rateCompared to CD4Multi-center seriesVenetoclax-based regimensSecond-line treatmentKaplan-Meier methodFollow-up timeSubgroup survival analysisCox proportional hazards modelsComprehensive clinical dataMulti-center studyProportional hazards modelFrontline therapyNodal involvementResponding patientsT-PLL
2022
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies
Boddu P, Senapati J, Ravandi‐Kashani F, Jabbour E, Jain N, Ayres M, Chen Y, Keating M, Kantarjian H, Gandhi V, Kadia T. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 2022, 129: 580-589. PMID: 36448227, PMCID: PMC12002038, DOI: 10.1002/cncr.34570.Peer-Reviewed Original ResearchConceptsPhase 1 studyT-cell prolymphocytic leukemiaComplete remissionContinuous infusionRefractory T-cell acute lymphoblastic leukemiaCentral nervous system toxicityIncomplete platelet recoveryRefractory lymphoid malignanciesT-cell acute lymphoblastic leukemiaUse of nelarabineFavorable clinical responseNervous system toxicityOverall response rateContinuous infusion scheduleAcute lymphoblastic leukemiaClinical responseCentral neurotoxicityLymphoblastic lymphomaMedian agePeripheral neuropathyInfusion scheduleSafety profilePatient populationLymphoblastic leukemiaPlatelet recoveryOutcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2022, 28: 187.e1-187.e10. PMID: 35081472, PMCID: PMC8977261, DOI: 10.1016/j.jtct.2022.01.017.Peer-Reviewed Original ResearchConceptsDisease-free survivalTreatment-related mortalityKarnofsky performance statusT-cell depletionVivo T-cell depletionAllogeneic hematopoietic cell transplantationInferior disease-free survivalHematopoietic cell transplantationOverall survivalT-cell prolymphocytic leukemiaT-PLLPerformance statusInternational BloodCell transplantationProlymphocytic leukemiaLong-term disease-free survivalMarrow Transplant Research databasePoor long-term survivalOutcomes of alloHCTPart of conditioningPost-transplantation relapseSuboptimal performance statusMyeloablative conditioning regimenReduced-intensity conditioningInferior overall survival
2020
Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR
Murthy H, Ahn K, Estrada-Merly N, Gowda L, Dholaria B, Bal S, Alkhateeb H, Jagadeesh D, Oran B, Nakamura R, Scott B, Sauter C, Foss F, kharfan-Dabaja M, Saber W. Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. Blood 2020, 136: 28-29. DOI: 10.1182/blood-2020-134793.Peer-Reviewed Original ResearchTreatment-related mortalityDisease-free survivalT-cell prolymphocytic leukemiaConditioning intensityLess treatment-related mortalityPoor long-term survivalNon-relapse mortalityPoor performance statusRetrospective multicenter studyHematopoietic cell transplantationOverall survival rateSmall retrospective seriesLimited treatment optionsMarrow Transplant ResearchAnalysis of patientsLong-term survivalRate of survivalAcute GVHDAllo-HCTChronic graftChronic GVHDNMA/Regimen intensityDurable remissionsHost disease
2018
False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restriction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply